ReviewClinical genitourinary cancer2019
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
Review in Clinical genitourinary cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.Journal for immunotherapy of cancer · 2022Trial
- Elevated preoperative inflammatory ratios (NLR/PLR) predict adverse pathology and poor surgical outcomes in metastatic renal cell carcinoma: a retrospective analysis.American journal of translational research · 2026Article
- Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment.Cancers · 2025Article
- Development and validation of a prediction model for the prognosis of renal cell carcinoma with liver metastases: a population-based cohort study.Frontiers in medicine · 2024Article
- Development and Preclinical Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2023Article
- Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.Journal for immunotherapy of cancer · 2023Article
- First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function.Cancers · 2023Article
- Microphysiological systems for solid tumor immunotherapy: opportunities and challenges.Microsystems & nanoengineering · 2023Review
- Review
- Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response.Biomedicines · 2021Article
- An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).The oncologist · 2021Article
- Prognostic Value of Plasma hPGCancers · 2021Article
- MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma.Cancer management and research · 2021Review
- Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.Medical oncology (Northwood, London, England) · 2020Article
- Article
- Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.Cancer discovery · 2019Review
- Emerging therapeutic agents for genitourinary cancers.Journal of hematology & oncology · 2019Review
- Review
- Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The incidence of renal-cell carcinoma has been increasing each year, with nearly one third of new cases diagnosed at advanced or metastatic stage. The advent of targeted therapies for metastatic renal-cell carcinoma (mRCC) has underscored the need to subtype tumors according to tumor-immune expression profiles that may more reliably predict treatment outcomes. Over the past 2 decades, several vascular endothelial growth factor (VEGF) and tyrosine kinase inhibitors have been the mainstay for first- and second-line treatment of mRCC. Very recently, immunotherapy checkpoint inhibitors have significantly changed the treatment landscape for patients with mRCC, particularly for first-line treatment of intermediate to poor risk mRCC patients. Now, combination immunotherapy as well as combinations of immunotherapy with targeted agents can significantly alter disease outcomes. The field of immuno-oncology for mRCC has unveiled a deeper understanding of the immunoreactivity inherent to these tumors, and as a result combination therapy is evolving as a first-line modality. This review provides a timeline of advances and controversies in first-line treatment of mRCC, describes recent advances in understanding the immunoreactivity of these tumors, and addresses the future of combination anti-VEGF and immunotherapeutic platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.